Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 890 participants.
Also called NCT05385770
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 890 participants
- Sponsor
- Registry
-
NCT05385770
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05385770. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-08 (actual); primary completion 2024-07-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
- Condition
- Essential Hypertension
- Intervention (Drug)
- AZM X mg + AML Y mg
- Intervention (Drug)
- AZM X mg + AML Y' mg
- Intervention (Drug)
- AZM X' mg + AML Y mg
- Intervention (Drug)
- AZM X' mg + AML Y' mg
- Intervention (Drug)
- AZM X mg
- Intervention (Drug)
- AZM X' mg
- Intervention (Drug)
- AML Y mg
- Intervention (Drug)
- AML Y' mg
- Lead sponsor
- Celltrion
Record details
- Record id
cardio:ct-nct05385770- Content hash
0b7dac92106b0b774665cf3980f495bee7e5e00d7836df6c2999f6abaadbb821